Patents Assigned to KUMAMOTO HEALTH SCIENCE UNIVERSITY
-
Patent number: 9421122Abstract: Disclosed is a thermotherapy in which a thermal gas such as hot vapor which is warm vapor is inhaled through a mouth or a nose, and the inhaled thermal gas spreads to every alveolus of lungs. Due to such a thermotherapy, the whole respiratory organ is warmed and, at the same time, heat energy is applied to blood through the alveoli of the lungs so that human body tissues are easily warmed within a short time by transferring the heat energy to whole parts of a human body by making use of the circulation of blood. Accordingly, not only a healthy person but also a patient can easily enjoy advantageous effects of a thermotherapy which is equal to or higher than advantageous effects of a sauna or hot spring.Type: GrantFiled: February 7, 2011Date of Patent: August 23, 2016Assignees: Kumamoto Health Science University (60%), Nexus Co., Ltd. (10%), Kagoshima University (30%)Inventors: Junichi Iiyama, Kazumi Kawahira
-
Patent number: 9080201Abstract: The present invention provides a method for simply and precisely measuring cholesterol in an HDL subfraction contained in a sample. This is a method for measuring cholesterol in HDL3 contained in a sample, which comprises reacting a sample with (1) a combination of a cholesterol ester hydrolase and a cholesterol oxidase or (2) a combination of a cholesterol ester hydrolase, an oxidized coenzyme and a cholesterol dehydrogenase in an aqueous medium containing: (a) a divalent metal salt; (b) an alkali metal salt selected from the group consisting of a sulfate, a nitrate, a carbonate, an acetate and a halide; and (c) dextran sulfate or a salt thereof, and measuring a substance formed or consumed in the reaction without separating and removing lipoproteins other than HDL3.Type: GrantFiled: March 15, 2012Date of Patent: July 14, 2015Assignees: KYOWA MEDEX CO., LTD., KUMAMOTO HEALTH SCIENCE UNIVERSITYInventors: Yuki Katayama, Hiroyuki Sugiuchi, Kazumi Matsushima
-
Patent number: 8796320Abstract: Provided is a 1,3,4-oxadiazole-2-carboxamide compound which has STAT3 inhibitory activity and is useful as an anticancer agent. Provided is a 1,3,4-oxadiazole-2-carboxamide compound represented by formula (I) or a pharmacologically acceptable salt thereof (in the formula, Ar represents a furyl group or the like; R1 represents a hydrogen atom or the like; and —X—Y represents a diaryl group such as a biphenyl group).Type: GrantFiled: December 28, 2010Date of Patent: August 5, 2014Assignees: General Incorporated Association Pharma Valley Project Supporting Organization, Pharma Design, Shizuoka Prefecture, Kumamoto Health Science University, Kabushiki Kaisha Yakult HonshaInventors: Akira Asai, Kenji Matsuno, Naohisa Ogo, Osamu Takahashi, Yoshiaki Masuda, Ayumu Muroya, Yasuto Akiyama, Tadashi Ashizawa, Tadashi Okawara
-
Publication number: 20130344518Abstract: The present invention provides a method for simply and precisely measuring cholesterol in an HDL subfraction contained in a sample. This is a method for measuring cholesterol in HDL3 contained in a sample, which comprises reacting a sample with (1) a combination of a cholesterol ester hydrolase and a cholesterol oxidase or (2) a combination of a cholesterol ester hydrolase, an oxidized coenzyme and a cholesterol dehydrogenase in an aqueous medium containing: (a) a divalent metal salt; (b) an alkali metal salt selected from the group consisting of a sulfate, a nitrate, a carbonate, an acetate and a halide; and (c) dextran sulfate or a salt thereof, and measuring a substance formed or consumed in the reaction without separating and removing lipoproteins other than HDL3.Type: ApplicationFiled: March 15, 2012Publication date: December 26, 2013Applicants: KUMAMOTO HEALTH SCIENCE UNIVERSITY, KYOWA MEDEX CO., LTD.Inventors: Yuki Katayama, Hiroyuki Sugiuchi, Kazumi Matsushima
-
Patent number: 8569238Abstract: The activated Factor XI is provided as an antitussive for cough caused by the stimulation at the tracheal bifurcation such as chronic cough. A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier, wherein the polypeptide chain consists of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as “FXIa”), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences.Type: GrantFiled: March 18, 2013Date of Patent: October 29, 2013Assignees: The Chemo-Sero-Therapeutic Research Institute, Ginkyo Academy Kumamoto Health Science University, National University Corporation Kumamoto UniversityInventors: Shintaro Kamei, Asami Shindome, Takayoshi Hamamoto, Hiroaki Maeda, Masaki Hirashima, Sachio Okuda, Misako Umehashi, Sachie Ogawa, Megumi Imuta, Norio Akaike, Kazuo Takahama, Ryoko Wada
-
Patent number: 8466290Abstract: The present invention provides a STATS inhibitor containing as an active ingredient, a quinolinecarboxamide derivative represented by the formula (I) (in the formula, W represents a bond or an alkylene chain; X represents O, S, or NR34; and R1 to R8 and R34 each represent H, halogen, alkyl, phenyl, furyl, thienyl, or the like), or a pharmacologically acceptable salt thereof.Type: GrantFiled: July 10, 2009Date of Patent: June 18, 2013Assignees: Pharma IP General Incorporated Association, Pharma Design, Inc., Shizuoka Prefecture, Kumamoto Health Science University, Kabushiki Kaisha Yakult HonshaInventors: Akira Asai, Kenji Matsuno, Naohisa Ogo, Takane Yokotagawa, Osamu Takahashi, Yasuto Akiyama, Tadashi Ashizawa, Tadashi Okawara
-
Publication number: 20120302524Abstract: Provided is a 1,3,4-oxadiazole-2-carboxamide compound which has STAT3 inhibitory activity and is useful as an anticancer agent. Provided is a 1,3,4-oxadiazole-2-carboxamide compound represented by formula (I) or a pharmacologically acceptable salt thereof (in the formula, Ar represents a furyl group or the like; R1 represents a hydrogen atom or the like; and —X—Y represents a diaryl group such as a biphenyl group).Type: ApplicationFiled: December 28, 2010Publication date: November 29, 2012Applicants: GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION, PHARMA DESIGN, INC., KABUSHIKI KAISHA YAKULT HONSHA, KUMAMOTO HEALTH SCIENCE UNIVERSITY, SHIZUOKA PREFECTUREInventors: Akira Asai, Kenji Matsuno, Naohisa Ogo, Osamu Takahashi, Yoshiaki Masuda, Ayumu Muroya, Yasuto Akiyama, Tadashi Ashizawa, Tadashi Okawara
-
Publication number: 20120225818Abstract: The activated Factor XI is provided as an antitussive for cough caused by the stimulation at the tracheal bifurcation such as chronic cough. A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier, wherein the polypeptide chain consists of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as “FXIa”), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences.Type: ApplicationFiled: August 5, 2010Publication date: September 6, 2012Applicants: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE, NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY, GINKYO ACADEMY KUMAMOTO HEALTH SCIENCE UNIVERSITYInventors: Shintaro Kamei, Asami Shindome, Takayoshi Hamamoto, Hiroaki Maeda, Masaki Hirashima, Sachio Okuda, Misako Umehashi, Sachie Ogawa, Megumi Imuta, Norio Akaike, Kazuo Takahama, Ryoko Wada
-
Publication number: 20110172429Abstract: The present invention provides a STATS inhibitor containing as an active ingredient, a quinolinecarboxamide derivative represented by the formula (I) (in the formula, W represents a bond or an alkylene chain; X represents O, S, or NR34; and R1 to R8 and R34 each represent H, halogen, alkyl, phenyl, furyl, thienyl, or the like.), or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: July 10, 2009Publication date: July 14, 2011Applicants: PHARMA IP GENERAL INCORPORATED ASSOCIATION, PHARMA DESIGN, INC., SHIZUOKA PREFECTURE, KUMAMOTO HEALTH SCIENCE UNIVERSITY, KABUSHIKI KAISHA YAKULT HONSHAInventors: Akira Asai, Kenji Matsuno, Naohisa Ogo, Takane Yokotagawa, Osamu Takahashi, Yasuto Akiyama, Tadashi Ashizawa, Tadashi Okawara